.png){kind=icon}
返回
Lead Generation and Optimization Based on Protein-Ligand Complementarity
.png){kind=icon}
OA
AI
DOI：10.3390/molecules15064382.png)
.png){kind=icon}
.png){kind=icon}
分享.png){kind=icon}
收藏
摘要
En 中文
This work proposes a computational procedure for structure-based lead generation and optimization, which relies on the complementarity of the protein-ligand interactions. This procedure takes as input the known structure of a protein-ligand complex. Retaining the positions of the ligand heavy atoms in the protein binding site it designs structurally similar compounds considering all possible combinations of atomic species (N, C, O, CH3, NH, etc). Compounds are ranked based on a score which incorporates energetic contributions evaluated using molecular mechanics force fields. This procedure was used to design new inhibitor molecules for three serine/threonine protein kinases (p38 MAP kinase, p42 MAP kinase (ERK2), and c-Jun N-terminal kinase 3 (JNK3)). For each enzyme, the calculations produce a set of potential inhibitors whose scores are in agreement with IC50 data and Ki values. Furthermore, the native ligands for each protein target, scored within the five top-ranking compounds predicted by our method, one of the top-ranking compounds predicted to inhibit JNK3 was synthesized and his inhibitory activity confirmed against ATP hydrolysis. Our computational procedure is therefore deemed to be a useful tool for generating chemically diverse molecules active against known target proteins.
Keyword:
lock-and-key problem
computational structure-based drug design
lead generation
lead optimization
AI总结
对已上传原文的论文进行重点信息的提取，主要内容包括：简要概述、研究摘要、背景介绍、关键亮点、图文解析、展望与总结。
期刊
IF:
4.6
论文数:
6.5W
被引数:
23.7W
机构
引用论文
.png){kind=icon}
Design and synthesis of the first generation of novel potent, selective, and in vivo active (benzothiazol-2-yl)acetonitrile inhibitors of the c-Jun N-terminal kinase设计和合成第一代新型有效，选择性和体内活性 (benzothiazol-2-yl) c 6月N末端激酶的乙腈抑制剂
PREAI
分享收藏分享收藏Correlation of EEG Slowing with Cognitive Domains in Nondemented Patients with Parkinson's DiseaseOAAI
OAAI分享收藏
查看更多内容